Tous Actualités
Suivre
Abonner SYGNIS AG

SYGNIS AG

EANS-News: SYGNIS announces three months results of fiscal year 2010/2011

Heidelberg (euro adhoc) -

  Corporate news transmitted by euro adhoc. The issuer/originator is solely
  responsible for the content of this announcement.
3-month report
Press release
Heidelberg,  August  12,  2010  -  SYGNIS  Pharma  AG  (Frankfurt:   LIO;   ISIN
DE0005043509; Prime Standard) today reports  financial  results  for  the  first
quarter of the fiscal year 2010/2011 ended June 30, 2010.
Financials
• Cash including marketable securities amounted to EUR13.1 million as of
June 30, 2010 (EUR19.4 million Q1 2009/2010).  Long  term  financial
liabilities amounted to EUR8.0 million resulting from  a  loan  which  is  not
due  for repayment before 2015.
• Total operating expenses for the quarter was EUR2.5 million, which  was
the same as the first three months of 2009/2010.
• The net loss in the first quarter was EUR-2.3 million, which was 
the same as the previous year.
Milestones
• Patient recruitment for the phase II efficacy study of the Company´s lead
      compound AX200, for the treatment of acute ischemic stroke, has
      significantly increased following the implementation of the modification
      of the AXIS 2 study protocol.
    • At its first meeting on 2 August 2010, the Data  Safety  Monitoring  Board
      (DSMB) reviewed the data on the safety  and  tolerability  of  the  AXIS 2
      study medication and advised on the  continuation  of  the  study  without
      changes.
Outlook
SYGNIS confirms its expectations of a net loss of around  EUR15  
million  for the current 2010/2011 fiscal year and a liquidity 
outflow of some EUR14 million.
Due to the modification to the AXIS 2 study protocol  and  the  
acceleration  of patient recruitment, the Company expects to present 
its initial findings of  the study by mid-2011.
In addition the Company  continues  to  evaluate  opportunities  to  
extend  its product pipeline and is working towards concluding a 
research alliance  for  the KIBRA project.
|Key financial figures for the first quarter of fiscal year         |
|2010/2011 ended June 30, 2010 and corresponding figures (IFRS)     |
|Numbers in million euros          |Q1 2010/2011    |Q1 2009/2010    |
|Revenues                          |0.1             |0.0             |
|Total expenses                    |2.5             |2.5             |
|EBIT                              |-2.4            |-2.4            |
|Net results for the period        |-2.3            |-2.3            |
|Intangible assets                 |21.8            |22.2            |
|Liquidity at end of quarter       |13.1            |19.4            |
|Equity                            |27.7            |34.1            |
|(equity ratio in %)               |(69)            |(72)            |
|Long-term financial liabilities   |8.0             |8.0             |
|Operating Cash Flow               |-2.3            |-3.0            |
The report on the first quarter which ended on June 30,  2010  is  
available  at the SYGNIS webpage at www.sygnis.de.
About SYGNIS Pharma SYGNIS Pharma AG, headquartered in Heidelberg,  
is  a  specialty  pharmaceutical company listed on the Prime Standard
of the German stock exchange.  The  Company is focused on the 
research, development and marketing  of  innovative  therapies for 
the treatment of disorders of the  Central  Nervous  System.  These  
include Stroke, Amyotrophic Lateral Sclerosis and neurological 
disorders resulting  from injuries to the brain or spinal cord. All 
these disorders are  characterized  by the fact that, as the disease 
progresses,  nerve  cells  are  damaged  and  die. Although there  is
great  medical  demand,  there  are  currently  no  or  only 
inadequate treatment options available.
One of the central elements  in  this  value-creation  chain  is  the
continued expansion of the existing product pipeline. This is 
achieved by the  development of new products as a result of SYGNIS´ 
own research  and  the  inorganic  growth through in-licensing 
agreements and  acquisitions.  By  means  of  specific  R&D programs 
at  SYGNIS,  new  pre-clinical  drug  candidates  are  identified  
and evaluated as well as preclinical  projects  initiated,  which  
are  offered  for inlicensing.
### Disclaimer Some statements included in this  press  release,  
relating  neither  to  proven financial results nor other  historical
data,  should  be  viewed  as  forward- looking, i.e. not definite. 
Such statements are  mainly  predictions  of  future results, trends,
plans or goals. These statements should not  be  considered  to be 
total guarantees since given their very nature they are subject to 
known  and unknown risks and imponderability and can be affected  by 
other  factors  as  a consequence of which the actual results, plans 
and goals  of  SYGNIS  Pharma  AG may deviate greatly from the  
established  conclusions  or  implied  predictions contained in such 
statements. SYGNIS does not undertake to  publicly  update  or revise
these statements in the light of new information  or  future  results
or for any other reason. ###
end of announcement                               euro adhoc

Further inquiry note:

For further information please contact:

SYGNIS Pharma AG:
|Dr. Franz-Werner Haas |
|Vice President Operations |
|+49 (0) 6221 454 812 |
|franz-werner.haas@sygnis.de |

Media-Contact:
Julia Phillips
Financial Dynamics
Tel.: +44 (0) 20 7269 7187

Branche: Biotechnology
ISIN: DE0005043509
WKN: 504350
Index: CDAX
Börsen: Frankfurt / regulated dealing/prime standard
Berlin / free trade
Hamburg / free trade
Stuttgart / free trade
Düsseldorf / free trade
Hannover / free trade
München / free trade

Plus de actualités: SYGNIS AG
Plus de actualités: SYGNIS AG
  • 29.06.2010 – 08:37

    EANS-News: SYGNIS announces Financial Results for fiscal year 2009/2010

    Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. annual report Heidelberg (euro adhoc) - Heidelberg, 29 June 2010 - SYGNIS Pharma AG (Frankfurt: LIO; ISIN DE0005043509; Prime Standard) today announced its financial results for the 2009/2010 fiscal year, which ended on 31 March ...

  • 11.02.2010 – 09:39

    SYGNIS announces nine months results of fiscal year 2009/2010

    Heidelberg (ots) - SYGNIS Pharma AG (Frankfurt: LIO; ISIN DE0005043509; Prime Standard) today reports financial results for the third quarter and the first nine months of the fiscal year 2009/2010 ended December 31, 2009. Financials - Cash including marketable securities amounted to EUR16.4 million as of December 31, 2009 (EUR26.0 million Q3 2008/2009). Long term financial liabilities ...

  • 10.11.2009 – 09:16

    EANS-News: Sygnis Pharma AG reports on second quarter 2009/2010

    Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. Accounting and Audits/Company Information/Financial Figures/Balance Sheet/quarterly report/6-month report Heidelberg (euro adhoc) - Heidelberg, November 10, 2009 - SYGNIS Pharma AG (Frankfurt: LIO; ISIN DE0005043509; Prime Standard) today ...